Drug the Undruggable Technologies
In this product category, you will find reports and other services providing you with the most uptodate business and competitive intelligence information on technologies to drug the undruggable targets
I use this drug for the last two years and never had any problem. It is commonly used for infections that involve the skin or ear such as acne, boils Hūn and impetigo. Tamoxifen (tam, 1-\[4-(2-methoxyethyl)phenoxy\]-3-(trifluoromethyl)benzamide) is an antiestrogen medication that is commonly prescribed to treat estrogen-dependent diseases in women, including the treatment of early-stage breast cancer.
Vitamin c serum does not contain fillers or additives. Its portfolio of funds propecia 28cpr riv 1mg prezzo carelessly includes private equity, alternative investments, hedge fund, real assets & real estate and commodities investments to support investors across the globe. The best sex pill for women who want to last longer.
Showing all 9 results
- November of 2022This report provides a landscape description and analysis of discovery and development of novel drug modalities targeting RNA from an industry perspective as of November 2019.€ 2350.00
- March of 2022This report describes and analyzes the field of Targeted Protein Degradation (TPD) from an industry perspective as of March 2022€ 2450.00
- October of 2021Landscape description and analysis of prodrug antibodies and cytokines employing conventional and novel masking technologies from an industry perspective as of October 2021€ 2250.00
- May of 2020This report package includes four reports for the price of two describing and analyzing the landscape of novel technologies to drug the undruggable targets from an industry perspective.
- May of 2020Report with a landscape analysis of Targeted Protein Degradation (TPD) technologies and of discovery and development of TPD drug candidates from an industry perspective as of May 2020€ 2050.00
- September of 2019This report provides a landscape description & analysis of discovery & development of small molecules against RNA as a drug target from an industry perspective€ 2050.00
- May of 2018These reports evaluate the competitive landscape of T-Cell Receptor (TCR)-based therapeutic cells and recombinant antibodies or antibody fusion proteins.
- May of 2018This report brings you up-to-date regarding key TCR-T players, technologies and product candidates, business models, deals and funding opportunities and analyzes the TCR-T pipelines and stakeholders in the field.€ 2150.00
- January of 2018This report informs you about key technologies to identify and validate intracellular targets, to generate TCRs and TCR fusion proteins, to discover TCR-like antibodies, and construct cell-penetrating peptides, proteins and...